Carmine Stengone, Contineum Therapeutics CEO
Contineum says it will seek $136M in IPO to back its mid-stage neuro drug
Contineum Therapeutics has set a price range for its upcoming IPO and plans to sell 8.8 million shares between $16 and $18 apiece.
Its expected …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.